Defense World
01 Feb 2026, 09:38 UTC · 41w ago
Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags
Impact · against what's priced in
Positive three-year EMBARK data for ELEVIDYS provides critical long-term evidence of disease modification in DMD patients. This supports the therapy's clinical value proposition and reduces the risk of long-term efficacy decay, potentially expanding its regulatory and commercial trajectory.
- SRPT+0.80
No priced-in read yet





